Stock Performance and Market Context
On 3 Feb 2026, Vivimed Labs Ltd (Stock ID: 612893) recorded a significant drop, closing at ₹8.38, down ₹0.44 from the previous close. The stock hit its lower circuit price band of 5%, reflecting the maximum permissible daily decline under current exchange regulations. This sharp fall came despite the broader Pharmaceuticals & Drugs sector gaining 2.81% on the same day, and the Sensex rising by 2.56%, highlighting the stock’s underperformance relative to its peers and the market benchmark.
The stock’s intraday high was ₹8.62, while the low matched the closing price at ₹8.38, indicating sustained selling pressure throughout the session. Total traded volume stood at 2.55 lakh shares, with a turnover of ₹0.21 crore, signalling moderate liquidity given the company’s micro-cap status with a market capitalisation of ₹73 crore.
Technical Indicators and Trend Analysis
Vivimed Labs is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests a bearish trend with limited immediate support levels. The stock has been on a downward trajectory for two consecutive sessions, cumulatively losing 9.7% over this period. Such a pattern often reflects deteriorating investor confidence and heightened risk aversion.
Investor participation has also waned, with delivery volumes on 2 Feb falling by 15.78% compared to the five-day average, indicating reduced conviction among buyers. This decline in delivery volume, coupled with the price drop, points to a lack of sustained demand and possible panic selling.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Investor Sentiment and Market Reaction
The sharp fall and circuit hit reflect a wave of panic selling, possibly triggered by negative sentiment or concerns over the company’s fundamentals. The stock’s Mojo Score currently stands at 31.0, with a Mojo Grade of Sell, downgraded from Strong Sell as of 1 Feb 2026. This downgrade indicates a slight improvement in outlook but still signals caution for investors.
Despite the downgrade, the stock remains under pressure, with a Market Cap Grade of 4, reflecting its micro-cap status and associated liquidity and volatility risks. The stock’s underperformance relative to the sector and benchmark indices suggests that investors are favouring other pharmaceutical stocks with stronger fundamentals or better growth prospects.
Supply-Demand Dynamics and Liquidity
On the supply side, the unfilled sell orders at the lower circuit indicate a significant imbalance between sellers and buyers. The inability of the market to absorb the selling pressure at higher prices forced the stock to close at the circuit limit. This scenario often leads to further volatility in subsequent sessions as investors reassess their positions.
Liquidity remains adequate for small trade sizes, with the stock’s traded value representing approximately 2% of its five-day average traded value. However, the relatively low turnover of ₹0.21 crore limits the ability of larger investors to enter or exit positions without impacting the price significantly.
Holding Vivimed Labs Ltd from ? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Outlook and Investor Considerations
Given the current technical weakness and negative market sentiment, investors should exercise caution with Vivimed Labs Ltd. The stock’s persistent underperformance against the sector and benchmark indices, combined with falling investor participation, suggests limited near-term upside.
Potential investors may want to monitor the stock’s ability to stabilise above key moving averages and watch for any fundamental developments that could alter its outlook. Meanwhile, existing shareholders should consider their risk tolerance and evaluate alternative investment opportunities within the pharmaceuticals sector, which has shown resilience and gains recently.
In summary, Vivimed Labs Ltd’s lower circuit hit on 3 Feb 2026 underscores the challenges faced by micro-cap stocks amid volatile market conditions. The combination of heavy selling pressure, unfilled supply, and technical weakness points to a cautious stance for investors in the near term.
Unlock special upgrade rates for a limited period. Start Saving Now →
